«

»

The effect of medical cannabis laws on pharmaceutical marketing to physicians

Abstract Although cannabis is federally prohibited, a majority of U.S. states have implemented medical cannabis laws (MCLs). As more individuals consider the drug for medical treatment, they potentially substitute away from prescription drugs. Therefore, an MCL signals competitor entry. This paper exploits geographic and temporal variation in MCLs to examine the strategic response in direct-to-physician marketing by pharmaceutical firms as cannabis enters the market. Using office detailing records from 2014-2018 aggregated to the county level, we find weak evidence of a relatively small and delayed response in substitute prescription drug- and opioid-related detailing. While these effect...

Read the full post at Wiley: Health Economics: Table of Contents
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive